Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 0.55 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.53 |
| ▸ | SCN1A | P35498 | 1/20 | 0.53 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.53 |
| ▸ | SCN2B | O60939 | 1/20 | 0.45 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093433 | 0.88 | SCN9A (0.54) | SCN9ASCN5ASCN1ASCN8ASCN2B | |
| SCHEMBL1095016 | 0.82 | SCN9A (0.56) | SCN9ASCN5ASCN1ASCN8A | |
| SCHEMBL29835208 | 0.82 | SCN9A (0.56) | SCN9ASCN5ASCN1ASCN8A | |
| SCHEMBL3478390 | 0.82 | SCN9A (0.57) | SCN9ASCN5ASCN1ASCN8A | |
| SCHEMBL15013492 | 0.81 | SCN9A (0.59) | SCN9A | |
| SCHEMBL1094279 | 0.81 | SCN9A (0.57) | SCN9ASCN5A | |
| SCHEMBL1094473 | 0.80 | SLC40A1 (0.52) | SCN9ASCN5ASCN1ASCN8A | |
| SCHEMBL20238716 | 0.80 | SCN9A (0.59) | SCN9ASCN5ASCN1ASCN8ASCN2B | |
| SCHEMBL29669015 | 0.80 | SCN9A (0.59) | SCN9ASCN5ASCN1ASCN8ASCN2B | |
| SCHEMBL20449281 | 0.78 | SCN9A (0.47) | SCN9ASCN5ASCN1ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110885319-B | Sulfonamide compounds as sodium channel blockers and uses thereof | 成都康弘药业集团股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20130338111-A1 | Sulfonamide Derivatives | ICAGEN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885SCN5A 19/4885SCN1A 23/4885 |
| US-20130338111-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885SCN5A 19/4885SCN1A 23/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885SCN5A 19/4885SCN1A 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.